Astra Zeneca Articles
NexGen founder's patent improves chemo
30 March 2009
Trilipix plus Crestor improves lipid targets
30 March 2009
AZD0837 "comparable" profile to VKAs in Ph II study
30 March 2009
Australia govt seeks to boost drug plants
30 March 2009
Retail drug sales in year to December 2008
30 March 2009
Study shows no higher cancer risk with Vytorin
27 March 2009
Stock Commentary - Europe - week to Mar 16, 2009
23 March 2009
Symbicort ups small airway function; study
23 March 2009
Dynavax and AZ extend asthma deal
23 March 2009
AstraZeneca analysis shows Arimidex superior to tamoxifen in sub-groups of breast cancer patients
23 March 2009
AstraZeneca challenges medical experts in Seroquel case
16 March 2009
Stock Commentary - Europe - week to Mar 9, 2009
16 March 2009
"No info to patients," EC urged by consumers
16 March 2009
Abraxane rights cost deepens Abraxis' loss
16 March 2009
GSK reduces CEO remuneration package
16 March 2009
Stock Commentary - Europe - week to mar 2, 2009
9 March 2009
AZ gets FDA complete response on Seroquel in GAD
9 March 2009
Symbicort approved in USA for COPD
9 March 2009
AZ e-mail reveals "buried"Seroquel data
9 March 2009
AZ awaits news of new indications for Seroquel
2 March 2009
AstraZeneca's Seroquel XR launched in USA
2 March 2009
AstraZeneca's Seroquel XR launched in USA
2 March 2009
AZ's sub-group analysis supports Crestor data
2 March 2009
Biota's six-month profit jumps 31% on GSK deal
2 March 2009
Stock Commentary - Europe - week to Feb 16, 2009
23 February 2009
PDCO refuses PIPs for Lilly, Allergan, Neurim and AZ
23 February 2009
PDCO confirms refusal of PIPs for Takeda and AZ
23 February 2009
Sweden's TLV rejects 1st-line use of Pfizer's Lipitor, cites "20 times" cost differential
23 February 2009
Japan stock market week to Feb 16, 2009
23 February 2009
UPDATE: Dutch NGO's CT claims rebutted by GSK and AZ
16 February 2009
Stock Commentary - Europe - week to Feb 9, 2009
16 February 2009
Dutch NGO's CT claims rebutted by GSK
16 February 2009
AZ gets nod in EU for two new Atacand doses
16 February 2009
AstraZeneca licenses preclinical-stage TRIs
16 February 2009
Stock Commentary - Europe - week to Feb 2, 2009
9 February 2009
"30,000" fake drug packs given to NHS patients
9 February 2009
Medarex rises 2.9% on $1M MedImmune fee
9 February 2009
Cubist's sales jump 47% on Cubicin sales
9 February 2009
AstraZeneca's net income slips 1.6% in 4th qtr as generic competition starts to bite
9 February 2009
Retail drug sales in year to November 2008
26 January 2009
Highlights of first PDCO meeting of 2009
26 January 2009
Stock Commentary - Europe - week to Jan 19, 2009
19 January 2009
MAP Pharma updates on two Ph III programs
19 January 2009
Pharma/biotech mergers and acquisitions in 2008
12 January 2009
AstraZeneca's Nobel link not a conflict of interest
12 January 2009
Stock Commentary - Europe - week to Jan 5, 2009
12 January 2009
MedImmune files MAA for LAIV
12 January 2009
Recipharm takes over AZ Swedish bio facility
12 January 2009
Lord Black: Big Pharma is "too cautious"
12 January 2009
AZ eyeing up a move into biosimilars
12 January 2009
PDCO meeting sees good news for J&J but a mix for GSK and AZ; Janssen pulls Invega app
12 January 2009
FDA asks for more info on Seroquel in MDD
12 January 2009
Tentative FDA OK for Teva's generic Seroquel
12 January 2009
AstraZeneca files Nexium sNDA for infant GERD
12 January 2009
MAP leaps on up to $900M deal with AZ
12 January 2009
AZ's Faslodex improves disease control
22 December 2008
Crisis in CEE pharma innovative market
22 December 2008
Retail drug sales in year to October 2008
22 December 2008
Palatin and AZ extend melanocortin receptor R&D alliance
15 December 2008
AstraZeneca returns IPI-504/IPI-493 rights to Infinity
15 December 2008
Stock Commentary - Europe - week to Dec 8, 2008
15 December 2008
B-MS and AZ extend accord to include Japan
15 December 2008
FDA warns AZ of off-label promotion case
15 December 2008
AZD3480 will not go into Ph III CDS testing
15 December 2008
FDA divided on safety of Serevent and Foradil ahead of panel meeting
15 December 2008
Merck & Co's 2009 outlook below predictions due to forex effects and restructuring costs
15 December 2008
US motavizumab appro delayed by info request
8 December 2008
Stock Commentary - Europe - week to Dec 1, 2008
8 December 2008
Biovail files ANDA for quetiapine
8 December 2008
Goldman's Symonds unveils early plans for R&D funding model focusing on specific areas
8 December 2008
Japan stock market week to Dec 1, 2008
8 December 2008
AZ's HRPC drug yields 45% drop in death risk
8 December 2008
Indonesia tells drug firms: "invest or go"
8 December 2008
Physicians expect higher Rxing post JUPITOR study
1 December 2008
Abraxis seeks to reacquire US Abraxane marketing rights from AZ
1 December 2008
Stock Commentary - Europe - week to Nov 24, 2008
1 December 2008
NSCLC data could signal comeback for AZ's Iressa
1 December 2008
GSK buys AstraZeneca OTC line for $253M
1 December 2008
AstraZeneca axes jobs, closes plants
1 December 2008
MSD publishes strong migraine trial results
1 December 2008
AstraZeneca does deal with Teva over generic Pulmicort
1 December 2008
AZ sells Swedish facility to Recipharm AB
24 November 2008
IFPMA re-elects Fred Hassan as president
24 November 2008
AZ promotes Rich Fante to president of US business
24 November 2008
FDA allows Teva's Pulmicort to AZ's protests
24 November 2008
AZ has mixed bag of results from Ph III trials
24 November 2008
Japan stock market week to Nov 24, 2008
24 November 2008
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
